Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Agomab

This is a fantastic opportunity to join a small team, work on transformative science, and take part in building an exciting, science-driven global company. We are on the lookout for a Corporate Counsel.

#vacancy #corporatecounsel

We are on the lookout for an experienced Senior Data Manager to expand our clinical team. Are you ready to play a critical role in overseeing the management of clinical data? Please check our vacancy.

#clinicaldata #vacancy #clinicaltrials

We will be moving to a new building in Antwerp. The reconstruction is ongoing and it will be great!

#talent #growth #Antwerp #Biotech

In our exciting next steps to take we are looking for a Head of RA who will be responsible for developing and driving the execution of the global regulatory strategies. Are you open for a fantastic opportunity to work on transformative science in a senior ambitious team? Please check our vacancy.

#Regulatory #submission

We’re on the lookout for the spider in the web for our Clinical Operations team. If you want to give general administrative support to make sure that the team can do their work efficiently. And you have a background in trial documentation, don't hesitate please check our vacancy.

#clinicaljobs

We are on the lookout for an energized Senior Manager External Engagement with a solid medical affairs and operational background, eager to build our investigator network, partner with patient associations and take on medical communications in support of our development programs. A key role in spreading Agomab’s ambition to change patient’s live. Please check our vacancy.
#patientengagement #clinicaltrials #medicalaffairs

It is great to be back at #JPM24, where our CEO Tim Knotnerus is pleased to present the latest developments in our programs.

We have dosed the first subject in our Phase 1 #ClinicalTrial evaluating AGMB-447 as a novel treatment option for patients with Idiopathic Pulmonary Fibrosis (IPF). AGMB-447 is an inhaled lung-restricted small molecule inhibitor targeting ALK5 that has the potential to safely block TGF-beta signaling, a known master regulator of fibrosis in IPF.
To learn more about the program and the clinical trial, read the press release here on our website: https://www.agomab.com

We are thrilled to announce that our colleague Natalie de Jonge is nominated for the TOPX Females to Follow Award in the category Rising star in Industry 2024. Natalie played an important role in the Phase 2 clinical study IND/CTA approvals for AGMB-129 program in the US, Canada and EU as well as the Fast Track designation for AGMB-129 in Fibrostenosing Crohn’s Disease. Besides her professional leadership, she has been a great team player and wonderful person. Please join us in voting for this rising star! https://lnkd.in/g79sCxXj

Topx Network

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

Google Maps

WordPress

Global Site Tag

Font Awesome

General Counsel

Ellen Lefever

Tim Knotnerus

Chief Financial Officer

Tolga Hassan

Translational Pharmacology Leader

Maarten Roy

Project Manager

Wendy Balemans

Project Manager Early Development

Caroline Meers

Head of Clinical Operations

Els Vanpee

Head of People

Mirjam Bollema

Chief Medical Officer

Philippe Wiesel

Thomas A Wynn

Ohad Hammer

John Haurum

Felice Verduyn

Virginia Morello

Co-founder

Pierre Kemula

Chief Executive Officer

Manuela Cazzanti

Federica Linty

Hans De Haard

Michael Saunders

Europe, Middle East, and Africa (EMEA) Female Founded Companies (Top 10K)

Biotechnology Companies With More Than 100 Employees

European Union (EU) Therapeutics Female Founded Companies

Europe, Middle East, and Africa (EMEA) Companies (Top 10K)

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.

Series D - AgomAb Therapeutics

Fidelity

Series C - AgomAb Therapeutics

Pfizer Breakthrough Growth Initiative

Series B - AgomAb Therapeutics

Redmile Group

AdBio partners

V-Bio Ventures

Series A - AgomAb Therapeutics

Ghent

Oost-Vlaanderen

Belgium

Europe

AgomAb Therapeutics

Alpha-9's $175m third-round heads latest biotech financings

Agomab Therapeutics Secures $89 Million in Series D Financing

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Erik van den Berg’s Post

Laura Bcf Career on LinkedIn: Join us for an exciting session on the Harvard Business Case, featuring…

Agomab Starts Phase 1 Clinical Study for AGMB-447 in ...

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

An oral small molecule GI-restricted inhibitor of ALK5 intended for the treatment of Fibrostenosing Crohn’s Disease, designed to inhibit ALK5 in the GI-tract with minimal systemic exposure.

An inhaled small molecule lung-restricted inhibitor of ALK5 intended for the treatment of Idiopathic Pulmonary Fibrosis, designed to inhibit ALK5 in the respiratory tract with rapid hydrolyzation in the bloodstream.

A Hepatocyte Growth Factor (HGF)-mimetic antibody acting as a full agonist of the MET receptor, developed for multiple inflammatory and fibrotic indications.

A Hepatocyte Growth Factor (HGF)-mimetic antibody acting as a partial agonist of the MET receptor, under development for various inflammatory and fibrotic diseases.

A pathway for patients with serious or life-threatening diseases to gain access to investigational medical products outside of clinical trials when no satisfactory alternatives are available.

Switzerland

Philippines

Asia

Australia

Oceania

India

Pliant Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for fibrotic diseases.

Pliant Therapeutics

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies for patients suffering from cancer.

Affimed

Cedilla Therapeutics is a biotechnology company that develops small molecules to modulate protein stability for the treatment of cancer and other diseases.

Cedilla Therapeutics

Arcellx is a biotechnology company focused on the development of adaptive and controllable cell therapies for the treatment of cancer and other diseases.

Arcellx

Cullgen is a biotechnology company that develops small molecule-based protein degradation technology for the treatment of diseases.

Cullgen

SEEKYO is a biotechnology company focused on the development of novel therapeutics for the treatment of cancer and other diseases.

SEEKYO

Core Biogenesis is a biotechnology company specializing in the development of regenerative medicine therapies and technologies.

Core Biogenesis

AgomAb is a biopharmaceutical company focused on the development of antibody-based therapies that modulate regenerative pathways to treat severe diseases.

news impact assignment basic	general
public peers	general	May 16, 2024 6:02 AM	95dde1e6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	34d253c8
crunchbase profile	general	Nov 25, 2024 9:47 AM	dbb459d7
li profile	general	May 16, 2024 6:02 AM	52d2e3d2
translate crunchbase fundingrounds	general	Nov 25, 2024 2:04 PM	7f6a2d87
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AGOMAB

AgomAb